Bicara Therapeutics Inc. cotiza a 17.33 USD y tiene una capitalización bursátil de $1.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human tran…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | — | $-0.82 | $-0.93 |
| Estimado | $-0.82 | $-0.83 | $-0.83 | $-0.65 |
| Sorpresa | — | — | +1.2% | -43.1% |
| Métrica | BCAX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -34.4% | -40.4% | +6.0% |
| ROA | -32.0% | -32.0% | 0.0% |
| Current Ratio | 14.58 | 2.84 | +11.74 |
| Debt / Equity | — | 0.28 | — |